久久视频在线视频精品-日韩亚洲变态另类中文-free性欧美69巨大-mm131巨爆乳美女少妇动态图

Recently, Endovactec?’s Hector? Multi-Branch Thoracic Stent Graft System (Hector?) has been approved to enter the Special Review Procedures for Innovative Medical Devices by China’s National Medical Products Administration (NMPA).

Hector? is designed to enable minimally invasive treatment of complex thoracic aortic aneurysms involving all three supra-aortic branches – an area for which no fully endovascular solutions are currently commercially available. Traditional techniques, such as the chimney and fenestration methods using standard grafts, present significant limitations in such cases. Hector? addresses this critical clinical challenge with a fully endovascular solution for three-branch reconstruction.

Building on nearly two decades of expertise in branched stent grafts, Endovastec? introduced the Castor? system, followed by the Cratos? system, which featured an enhanced delivery system. Now, as the company’s first multi-branch stent graft, Hector? further expands endovascular aortic treatment to the entire aortic arch, addressing a significant clinical challenge.

Hector? integrates several key innovations, including an off-the-shelf triple-branch stent graft design, which is capable of adapting to the variable anatomical structures of the aortic arch, a swift deployment system that preserves supra-aortic vessels blood flow during operation, and a flexible yet stable bridging stent with tip-capture design.

Currently, Hector? has successfully completed multiple clinical implantations in several countries, including Switzerland and Italy. With fast-track designation by NMPA, Hector? will become available in China more quickly, supporting broader access to advanced and effective medical solutions.